Yet again, the whole Buzdar issue is spurious when researched just as so many of the hype and speculation posted by some.
NWBO did not receive any "rebuke" from any clinical trial site about this issue [I am sure they would have if it was of such importance] NWBO had previously stated that it would release interim data on an ongoing basis regarding the DCVax-Direct Phase 1/2 clinical trial. The apparent 'disclosed data' originated from medical files sent to the company from the trial sites and a CRO. AF had again purposely attacked NWBO [not for the first time] and yet issuing interim results the way NWBO did is not even unusual for an unblinded open-label study like DCVax. So yet again we see facts are twisted to give sensationalised headlines putting doubt into investors for their own self interests.
Market Data 
Markets 
AI
